Photo from archive.org
The approval of the COVID-19 mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization and several other vaccines likely… Click to show full abstract
The approval of the COVID-19 mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization and several other vaccines likely to follow. These vaccines all utilize relatively new vaccine production platforms to produce the SARS-CoV2 Spike protein. This review discusses how these platforms work, what advantages they offer and the gaps that remain in public health efforts to control the COVID-19 pandemic.
Keywords:
leveraging new;
covid vaccines;
vaccines leveraging;
set covid;
covid;
next set
Journal Title: Clinical Therapeutics
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Therapeutics
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!